Adv Surg. 2026 Sep;60(1):49-64. doi: 10.1016/j.yasu.2026.03.004. Epub 2026 May 19.
ABSTRACT
Landmark trials have demonstrated that residual microscopic disease in the undissected axilla does not translate to a higher risk of nodal recurrence, which laid the groundwork for trials examining the omission of axillary surgery. The SOUND and INSEMA randomized trials demonstrated no difference in disease-free survival in patients with small, cN0 breast cancer treated with or without sentinel lymph node biopsy (SLNB). Postmenopausal patients with luminal breast cancer undergoing lumpectomy with a normal preoperative axillary ultrasound are ideally suited for omission of SLNB, as systemic therapy decisions are increasingly based on genomic assays rather than pathologic nodal status.
PMID:42556961 | DOI:10.1016/j.yasu.2026.03.004